Exercise 8 Direct Antiglobulin Test (DAT) : Objectives
Exercise 8 Direct Antiglobulin Test (DAT) : Objectives
Exercise 8 Direct Antiglobulin Test (DAT) : Objectives
Objectives:
Introduction
The Direct Antiglobulin Test (DAT) is a simple test used to determine if red cells have been coated in vivo
with immunoglobulin, complement or both, which are specific types of proteins. This test may be performed
on any patient as part of differential diagnosis when the presence of hemolysis has been established or as part
of a work up to determine the cause of hemolysis or anemia.
A positive DAT indicates that the red cells have been coated in-vivo with protein. Both immunoglobulin and
complement are proteins. It is important, in most cases, to test for the presence of both. The test should be
performed with polyspecific antiglobulin reagent which contains antibodies to IgG and the C3d component
of complement. The only exception to this is cord blood testing. Cord blood is tested with monospecific anti-
IgG reagent since this is the only coating protein expected.
The specimen of choice for the DAT is an EDTA specimen. EDTA prevents in-vitro fixation of complement
by chelating the calcium needed for C1 activation. If a clotted specimen is used a false positive result may
be obtained due to non-specific binding of complement to the red blood cells in-vitro. The clotted sample can
be used but if a positive reaction is obtained with anti-C3b it must be verified with a test performed on an
EDTA sample.
The DAT is used to assist in the diagnosis of hemolytic disease of the fetus and newborn (HDFN),
autoimmune hemolytic anemia, sensitization of red cells due to drugs, investigation of transfusion reactions
and hemolysis due to ABO-incompatible platelet transfusions or ABO- mismatched organ transplants.
A positive DAT alone is not diagnostic. The interpretation of the possible clinical significance requires
knowledge of the patient’s history which includes:
These are vital pieces of information which must be obtained when working up a positive DAT.
Dialogue with the attending physician is important. Clinical considerations together with laboratory data
should dictate the extent to which a positive DAT is evaluated.
Principle
The principle of the procedure is based on the test developed by Coombs, Mourant and race for the detection
of antibodies which attach to red cells but that do not produce direct agglutination. A drop of red cells is
thoroughly washed. Anti-human globulin (AHG) and/or anti-C3 are added to the washed red cells. If the red
cells have been coated the AHG or anti-C3 will bind producing visible agglutination.
Discussion
This lab will determine whether or not an infant's red blood cells have been sensitized in-vivo by maternal
antibody by performing the direct antiglobulin test (DAT). Please remember that the DAT is a procedure that
is performed on cord bloods, infants, adults and donor units. The purpose of the test in this student laboratory
session is to detect sensitization of fetal cells by maternal antibody, but keep in mind that this test is performed
in many other situations.
For diagnosis of HDFN the specimen for testing is obtained from the baby's umbilical cord immediately
following birth. The preferred method for sample collection is to use a syringe to withdraw the sample from
the umbilical cord to prevent contamination with Wharton's jelly. Wharton's jelly is a gelatinous substance
which protects the umbilical cord from collapsing and gives it an elastic and cushion affect. If the cord
specimen becomes contaminated with this substance it will cause non-specific agglutination of the red cells
(false positives). False positive reactions are usually discovered when the ABO/D typing is performed. All
forward typing tubes are positive, an Rh control is run, and it is also positive, invalidating the test. It is a
When a positive cord blood DAT is obtained a series of tests are required to determine the specificity of the
offending antibody.
1. An ABO/D type is performed on the cord blood. This information, when compared with the
maternal ABO type, will determine whether or not ABO antibodies are involved. Please remember
that a reverse type cannot be performed on babies, as the ABO antibodies present in their
serum/plasma are of maternal origin
2. Type and Screen is performed on the maternal sample to identify the specificity of the maternal
antibody coating the cord cells. If the mother is group O, the antibody screen is negative and the infant
is an A or a B then ABO HDN is suspected. If the antibody screen is positive and a panel study
reveals the presence of an unexpected antibody, the clinical significance of the alloantibody must be
determined. The results of the antibody screen on the mother will determine which type of elution to
perform, as some elution procedures are best at recovering alloantibodies, while others are best at
recovering immune ABO antibodies.
3. An elution may be performed on the cord cells to identify the specificity of the coating antibody.
a. If the mother's antibody screen is positive, a panel study is done on the mother's serum. If a
clinically significant antibody is identified an acid elution must be performed on the infant's
cord cells to verify that the antibody in the mother's serum is, indeed, coating the baby's cells.
b. If the mom's screens are negative and she is ABO incompatible with her infant then a heat
elution is performed on the infant's cord cells to verify the presence of maternal ABO
antibodies coating the cord cells.
The results of the DAT on the cord blood, ABO/D type of infant, ABO/D type of maternal sample, results of
maternal antibody screen and, if necessary, results of panel identification, will determine the classification
of HDFN. HDFN is classified as follows:
1. ABO - most common and mildest form of HDFN. Most commonly detected in group A or B infants
born of group O mothers. The key findings are a positive cord blood DAT, an A or B infant, group
O mother and a negative antibody screen on the mother.
2. “Other” - May cause mild to severe HDFN. This type of HDFN is due to immune antibodies OTHER
THAN anti-D. The key finding is positive cord blood DAT, a positive antibody screen on the mother,
identification of a clinically significant antibody in the maternal sample and elution of the clinically
significant antibody from the cord cells. IMPORTANT: If the mother is ABO incompatible with the
infant the eluate must be run against A and B cells as ABO antibodies may be coating the cord cells
as well.
3. Anti-D - This is the most severe form of HDFN. It may be due to anti-D alone or anti-D plus other
Rh antibodies. The key findings are a positive DAT on the cord blood, D positive infant, D negative
mother with a positive antibody screen, identification of immune anti-D in the maternal sample and
elution of anti-D from the cord cells.
Examples:
DAT results
on cord cells
NEGATIVE POSITIVE
Rh on cord cells
Interpretation
1. Negative, no in-vivo sensitization detected.
2. Positive, in-vivo sensitization detected; elution studies should be performed. The type of elution
done will be determined by the results of the mother's type and screen. *At this time, perform the
Type and Screen on the maternal specimen according to your previous exercise.
While the type and screen on the mother is incubating, perform an ABO/D on the baby's cells. A
reverse type cannot be performed on an infant since all antibodies in the baby are of maternal
origin. After all results are in, look at the flow chart to determine which eluate will be performed
next week.
Name_________________________________ Date_________________________________
RETYPE
RETYPE
RETYPE
RETYPE
Name_________________________________ Points: 33
3. What three reagents may be used in the DAT procedure? (1.5 point)
a.
b.
c.
4. What is the sample of choice for the DAT? Why? (2 points)
5. The DAT is used to assist in hemolysis associated with what four (4) clinical conditions. (2
points)
a.
b.
c.
d.
6. What 3 items in the patient history are crucial in determining the clinical significance of a positive
DAT? (3 points)
a.
b.
c.
7. State the principle of the DAT procedure. (1 point)
9. What is the source of the specimen used for the DAT on newborns?(1 point)
11. What problems will contamination of the cord blood sample with Warton’s jelly cause? (1 point)
15. What must be done for the infant if the HDFN is severe at birth. (1 point)
M om ABO/D ABO Antibodies Immune Antibody Baby ABO/D Donor Blood Points
Identified